Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies
Journal of Clinical Medicine · 09.02.2023 · 12 (4) · 1381
DOI: 10.3390/jcm12041381 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 09.02.2023. Verfasst von Denise Battaglini und 7 weiteren Autor:innen. Beteiligte Einrichtung: Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, 16132 Genoa, Italy. Die Arbeit wurde bisher 88-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Over the last decade, the management of acute respiratory distress syndrome (ARDS) has made considerable progress both regarding supportive and pharmacologic therapies. Lung protective mechanical ventilation is the cornerstone of ARDS management. Current recommendations on mechanical ventilation in ARDS include the use of low tidal volume (VT) 4–6 mL/kg of predicted body weight, plateau pressure (PPLAT) < 30 cmH2O, and driving pressure (∆P) < 14 cmH2O. Moreover, positive end-expiratory pressure should be individualized. Recently, variables such as mechanical power and transpulmonary pressure seem promising for limiting ventilator-induced lung injury and optimizing ventilator settings. Rescue therapies such as recruitment maneuvers, vasodilators, prone positioning, extracorporeal membrane oxygenation, and extracorporeal carbon dioxide removal have been considered for patients with severe ARDS. Regarding pharmacotherapies, despite more than 50 years of research, no effective treatment has yet been found. However, the identification of ARDS sub-phenotypes has revealed that some pharmacologic therapies that have failed to provide benefits when considering all patients with ARDS can show beneficial effects when these patients were stratified into specific sub-populations; for example, those with hyperinflammation/hypoinflammation. The aim of this narrative review is to provide an overview on current advances in the management of ARDS from mechanical ventilation to pharmacological treatments, including personalized therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Anesthesia and Intensive Care, San Martino Policlinico Hospital, IRCCS for Oncology and Neuroscience, 16132 Genoa, Italy.
- Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, Whitechapel, London E1 1BB, UK.
- Laboratory of Pulmonary Investigation, Carlos Chagas Filho Institute of Biophysics, Federal University of Rio de Janeiro, Rio de Janeiro 21941-901, Brazil.
- Department of Surgical Sciences and Integrated Diagnostics, University of Genoa, 15145 Genoa, Italy.
ORCID-Profile: Denise Battaglini, Brigitta Fazzini, Patricia R M Rocco
Zitieren
APA
Battaglini, D., Fazzini, B., Silva, P. L., Cruz, F. F., Ball, L., Robba, C., Rocco, P. R. M., & Pelosi, P. (2023). Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies. Journal of Clinical Medicine, 12(4), 1381. https://doi.org/10.3390/jcm12041381
Vancouver
Battaglini D, Fazzini B, Silva PL, Cruz FF, Ball L, Robba C, et al. Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies. Journal of Clinical Medicine. 2023;12(4):1381. doi:10.3390/jcm12041381
BibTeX
@article{Battaglini2023,
author = {Battaglini, Denise and Fazzini, Brigitta and Silva, Pedro Leme and Cruz, Fernanda Ferreira and Ball, Lorenzo and Robba, Chiara and Rocco, Patricia R M and Pelosi, Paolo},
title = {Challenges in ARDS Definition, Management, and Identification of Effective Personalized Therapies},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {4},
pages = {1381},
doi = {10.3390/jcm12041381}
}
EUVIMED